Amendments to the Specification:

Please replace paragraph 2, on page 9, beginning at line 7 with the following amended paragraph:

--The dose of the pharmaceutical composition of the present invention differs according to the age, the body weight, the severity of symptoms of, and the route of administration in, a patient with myocardial infarction or a patient potentially developing myocardial infarction. When the substance as an active ingredient is a natriuretic peptide, the pharmaceutical composition can be administered at a dose of 0.1 μg/kg/min to 0.2 μg/kg/min, and is preferably administered in a dose of 0.025 μg/kg/min to 0.1 μg/kg/min, by the continuous intravenous route. ~~When the administration is made by coronary infusion, a higher dose of the active ingredient can be administered than in the case of an intravenous administration.~~ --